Top Injectable Manufacturer in Fiji – Reliable Pharmaceutical Solutions
Top Injectable Manufacturer in Fiji – Reliable Pharmaceutical Solutions
Last Updated: September 10, 2026
TL;DR: Fiji publishes exactly which foreign regulators it recognises, and India is not among them. For government supply, the regulator's own routing table says a product both registered and manufactured outside a PIC/S country is not accepted for prequalification. The open doors are WHO prequalification of the product, or a marketing authorisation from a stringent or WHO-listed authority — a solvable engineering problem, not a closed market.
Key Takeaways
Fiji recognises regulators that WHO designates as stringent or WHO-listed, the New Zealand regulator, and regulators of PIC/S member countries; India is in none of those categories.
CDSCO does appear on WHO's maturity-level listing, but the scope recorded against it is vaccines — it is not a medicines credential for a sterile injectable.
WHO-GMP certified and WHO prequalified are different things, and Fiji asks for two GMP certificates when the site sits in a country it does not recognise.
Government supply and the private market are separate doors with separate rules, and prequalification is not by itself an order from the health ministry.
Introduction: What an Injectable Manufacturer in Fiji Has to Prove
Fiji is the most legible market this series has examined, and the legibility cuts both ways. The Medicines Regulatory Authority's prequalification guidance of March 2024 states which regulators it recognises: those WHO designates as stringent or WHO-listed authorities, the regulator of New Zealand, and the regulators of countries belonging to PIC/S, with a residual discretion to consider others case by case. India appears in none of the three named limbs, and India is not a PIC/S member.
It is worth being precise about the one place India does appear, because it is easy to over-read. CDSCO is on WHO's transitional listed-authority register at maturity level 3 — but the scope recorded against it is vaccines. Every authority whose scope reads medicines and vaccines qualifies for a sterile injectable; an entry scoped to vaccines does not. Separately, the Indian Pharmacopoeia Commission signed a memorandum with Fiji's health ministry in Suva in May 2025 recognising the Indian Pharmacopoeia as one of the standards for Indian-made products used in Fiji. That is recognition of a book of standards, not of an agency, and we found no Fiji-side instrument implementing it.
What Sets a World-Class Injectable Manufacturer in Fiji Apart
The regulator publishes a routing matrix, and one row decides the question for most Indian exporters: a product registered in a non-PIC/S country and manufactured in a non-PIC/S country is not accepted for prequalification. That is India to India, in the Authority's own words rather than by our inference, with a shortage-based case-by-case exception as the only stated relief. A second requirement sharpens it. Where the manufacturing site sits in a country Fiji does not recognise, the guidance asks for two GMP certificates — the local one, plus one issued by a regulator Fiji does recognise — and points applicants at the European GMP database. A WHO-GMP certificate from an Indian state licensing authority satisfies the first of those and not the second.
So the honest answer is that the ordinary route is closed and two specific doors are open. The first is WHO prequalification of the finished product, where the guidance makes the country of manufacture explicitly irrelevant. The second is a marketing authorisation held in a country whose regulator Fiji recognises — an EU member state, the United Kingdom, Australia, Japan, Canada, Switzerland, the United States or New Zealand — after which the Indian origin of the site stops being the deciding fact. Both are multi-year investments rather than paperwork, and a manufacturer that tells a Fijian buyer otherwise is not being straight with them.
Quality Systems Behind Every Sterile Injectable We Ship to Fiji
Those two doors are reachable from the same quality system, which is why the investment compounds. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic processing or terminal sterilisation, media fills and environmental monitoring. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for endotoxins and Karl Fischer for moisture in lyophilised vials. Stability runs on ICH Q1A protocols with Q1B photostability, on the climatic zone for a humid tropical Pacific destination rather than a temperate default.
Dossiers are assembled in CTD format, with ACTD available where a regulator prefers it, which is the format both a WHO prequalification submission and a stringent-authority filing are built from. One practical detail surprises people: Fiji expects the pack presented to it to be identical to the pack approved in the reference market. The instinct to design a Fiji-specific carton is wrong, and rebuilding artwork late is a common cause of avoidable delay.
Working out which door into Fiji fits your product? Talk to our regulatory team about prequalification dossiers, reference-market strategy and pack-identity requirements.
Why Farbe Firma is the Trusted Injectable Manufacturer in Fiji for Global Buyers
Fiji has two doors, not one, and conflating them causes most of the confusion we see. For government supply, an overseas supplier may apply to the Authority directly; the manufacturer and the product are prequalified separately, and goods imported by Fiji Pharmaceutical and Biomedical Services against a prequalification are exempt from per-shipment import permits. For the private market, the applicant is a locally registered and licensed Fijian entity, which lists the product and holds the import permit — and that listing is applicant-specific and not transferable without the Board's approval, a real commercial lock-in worth weighing when a distributor is chosen. We would add that the evidentiary requirements published in the prequalification guidance are written for prequalification, and a manufacturer should confirm with the Board what applies to a private-market listing rather than reading one across to the other.
The buyer is also not always the ministry. For HIV and tuberculosis commodities the operative purchaser under a health-procurement project signed in July 2024 is UNDP, applying the Global Fund's quality-assurance policy, which accepts WHO prequalification, a stringent authority, a WHO-listed authority, or expert-review-panel review. UNFPA's Pacific presence is based in Fiji, with the national warehouse acting as a node for several countries. These donor rules are frequently the gate that actually binds, and they point at the same two doors as the national regulator: solving for WHO prequalification solves for several buyers at once.
The market itself is modest. The population stood at 928,784 in 2024, current health expenditure at 3.62% of GDP in 2023, with 8.31% paid out of pocket and 11.64% financed externally, all on WHO Global Health Expenditure Database figures. We would caution against reading trends into that series: a 2021 spike reflects a pandemic-era GDP denominator, and a later movement in the out-of-pocket share reflects a methodology change. On costs and timelines we print nothing: no fee schedule and no statutory processing time appears in the Act, the regulations or any of the guidance documents we read. One further correction, because it circulates widely: the twelve-month shelf-life-on-arrival rule often quoted here is India's import rule, not Fiji's, and we found no Fijian equivalent.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Does Fiji accept Indian regulatory approval for medicines?
Not as a recognised approval. Fiji recognises WHO-designated stringent and WHO-listed authorities, the New Zealand regulator, and regulators of PIC/S member countries, and India falls into none of those. The Authority's own routing table records that a product registered and manufactured in a non-PIC/S country is not accepted for prequalification, with a shortage-based exception decided case by case.
Is WHO-GMP certification enough to supply Fiji?
No, and the distinction matters. WHO-GMP certification is a GMP credential issued by an Indian licensing authority; WHO prequalification is an assessment of a specific product by WHO. Where the site is in a non-recognised country, Fiji's guidance asks for a second GMP certificate issued by a regulator it does recognise, which a WHO-GMP certificate does not supply.
Does the Indian Pharmacopoeia memorandum open a registration pathway in Fiji?
No. The memorandum signed in Suva in May 2025 recognises the Indian Pharmacopoeia as one of the standards for Indian-made products used in Fiji. That is a book of quality standards, not an agency recognition, and waives no registration requirement. We found no Fiji-side implementing instrument, and the Authority's guidance still names the British, European, International and United States pharmacopoeias.
Does a foreign manufacturer need a local agent in Fiji?
It depends on the door. For government supply an overseas supplier may apply for prequalification directly. For the private market the applicant must be a locally registered and licensed Fijian entity, which then owns the listing and holds the import permit — so a blanket claim that a local agent is always legally required would be wrong, and so would the opposite.
What do registration and prequalification cost in Fiji, and how long do they take?
We will not print a figure for either. No fee schedule and no statutory timeline appears in the Medicinal Products Act, its regulations, or any of the Authority's guidance documents we were able to read. Both should be confirmed with the Authority directly, and any plan that depends on a date should be built after that confirmation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Farbe Firma Pvt Ltd — WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Exporting to 30+ countries. Email: director@farbefirma.org | Request a Quote / View Products / FAQ / Blog
Comments